SOURCE-LINKED STUDY SUMMARY
International expert panel review for the use of resmetirom and semaglutide in the management of MASH-related fibrosis: clinical practice update.
Abstract summarizedQuality not appraised
- What was studied
- An expert-panel review of resmetirom and semaglutide in metabolic liver disease with significant fibrosis.
- Who / model studied
- Research and guidance concerning noncirrhotic metabolic dysfunction-associated steatohepatitis with significant liver fibrosis. This is a review, not a newly enrolled patient cohort.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- The panel brings together trial data, medicine labels and clinical experience to discuss diagnosis, treatment selection, monitoring and response assessment. The abstract reports no new effect sizes or head-to-head comparison.
- Limitations & context
- The proposed care framework is expected to change as long-term outcome data become available. It should not be read as new experimental proof for combining the medicines.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1136/gutjnl-2026-340031